Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
published : This month entities : Bristol-myers squibb company save search
Pomerantz Law Firm Announces the Filing of a Class Action Against VinFast Auto Ltd. and Certain Officers - VFS
Published: 2024-04-12 (Crawled : 20:00) - prnewswire.com
FICO S | $1162.25 0.78% -0.06% 210K
|
Technology Services
| Email alert
Add to watchlist
VFS | $2.7 -0.74% -0.74% 2.4M
|
| Email alert
Add to watchlist
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
| Email alert
Add to watchlist
BSAQ | $10.2 2.45% 380
|
| Email alert
Add to watchlist
Eczema Therapeutics Market size is set to grow by USD 5.81 bn from 2024-2028,high prevalence of atopic dermatitis boost the market- Technavio
Published: 2024-04-08 (Crawled : 18:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 2.24%
H: 0.0%
C: -0.8%
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: -3.43%
H: 6.21%
C: 6.21%
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: -0.25%
H: 1.1%
C: -0.17%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.05%
H: 0.43%
C: -0.27%
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: -0.08%
H: 0.04%
C: -0.35%
BHC | $8.6 -0.69% 0.0% 2.1M
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: -7.27%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.77%
H: 1.63%
C: 0.35%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.84%
H: 0.0%
C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 0.18%
H: 0.3%
C: 0.19%
eczema dermatitis set therapeutics market
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
Published: 2024-04-05 (Crawled : 14:00) - biospace.com/
TSVT | $4.65 -8.1% -8.82% 710K
|
|
| O: 7.98%
H: 9.06%
C: -9.06%
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: -0.41%
H: 0.51%
C: 0.25%
fda for therapy
European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Published: 2024-04-03 (Crawled : 08:00) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: -0.08%
H: 0.3%
C: -0.99%
reblozyl anemia approval treatment
Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals
Published: 2024-04-02 (Crawled : 12:00) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 0.21%
H: 0.47%
C: -0.68%
report
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.